Biovail Company Description
Specialty pharmaceutical firm Biovail has unveiled a number of improved versions of existing drugs using its oral drug-delivery technologies. The company makes extended-release versions of GlaxoSmithKline'santidepressant Wellbutrin (Wellbutrin XL), Sanofi-Aventis' blood pressure medication Cardizem (Cardizem LA), and J&J's chronic pain drug Ultram (Ultram ER). Other products include genital herpes treatment Zovirax, anti-hypertensive Tiazac, and diabetes therapy Glumetza (licensed from Depomed). Biovail is also developing new central nervous system (CNS) therapies. The firm sells its products through marketing partnerships and direct sales representatives, primarily in the US and Canada.
View the Comprehensive Company Description for Biovail
The Company Description provides a historical perspective of Biovail's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Biovail's evolution in the marketplace.
